Direct thrombin inhibitors

Haemostasis

Volumn 29, Issue SUPPL. 1, 1999, Pages 76-78

  Anand, S ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON GENERAL HOSPITAL   (Canada)

Author keywords

Acute coronary syndromes; Bivalirudin; Direct thrombin inhibitors; Hirudin

Indexed keywords

HEPARIN; HIRUDIN; HIRULOG; THROMBIN INHIBITOR;

BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

EID: 0033402412     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054117     Document Type: Conference Paper

References (2)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
2. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet 1999;353: 429-438.